However, due to the small sample size of this trial, definitive conclusions about effectiveness and cost-effectiveness of routine follow-up with respect to disease outcomes were not assessable [9]. In 1996 and 2006, two multicenter, randomized, controlled trials showed no differences in terms of recurrence-related clinical events rate and small molecule library screening health-related QoL between follow-up performed by a medical oncologist or by a PCP [10] and [11]. However, median follow-up of both trials was short (18 months and 3.5 years, respectively) and studies were underpowered to evaluate the impact on OS. To date, the ASCO

[12] and the NCCN (National Comprehensive Cancer Network) [14] guidelines recommend breast self-examination, annual bilateral mammography and periodic history and physical examination (every 3–6 months for the first 3 years, then every 6–12 months for 2 years or every 4–6 months for 5 years, respectively, then every 12 months). They also underline the importance of counseling about symptoms of recurrence and active lifestyle. Moreover, they recommend periodic pelvic examinations for every woman, in particular patients taking tamoxifen, who are at increased risk of endometrial cancer, and bone mineral density determination for women undergoing an aromatase

inhibitor or who experience ovarian failure secondary to treatment. Physicians should assess and encourage adherence to adjuvant endocrine therapy, and women at high risk for familial breast cancer syndromes should be referred for genetic counseling. In asymptomatic patients, there are no data to indicate that other laboratory or imaging tests (e.g. BKM120 blood counts, routine chemistry tests, chest X-rays, bone scans, liver US exams, computed tomography (CT) scans, positron emission tomography (PET) scans or any tumor markers such as CA15-3 or CEA) can produce Dichloromethane dehalogenase a survival benefit. The ESMO guidelines [15] focus attention to survivorship care, highlighting

that the purposes of follow-up are also to evaluate and to treat therapy-related complications (such as menopausal symptoms, osteoporosis and second cancers) and to provide psychological support and information in order to enhance returning to normal life after BC. Table 1 summarizes current guidelines on breast cancer follow-up. Currently, no specific trials were conducted to evaluate the best follow-up strategy in particular population, such as male BC, elderly patients, very young patients, and BRCA1-2 mutation carriers. In clinical practice intensive follow-up is a widespread reality and it costs 2.2–3.6 times more than guidelines-compliant follow-up [16], as a result of non-mammographic tests performed in the absence of any warning signs or symptoms of recurrence [17]. The ASCO included BC surveillance in the top-five list of oncological practices that could be improved and simplified in order to reduce costs [18].